166Ho-labeled hydroxyapatite particles: A possible agent for liver cancer therapy

Cancer Biotherapy and Radiopharmaceuticals

Volumn 24, Issue 1, 2009, Pages 7-13

  Das, Tapas ^a   Chakraborty, Sudipta ^a   Sarma, Haladhar D ^a   Venkatesh, Meera ^a   Banerjee, Sharmila ^a  

^a BHABHA ATOMIC RESEARCH CENTRE   (India)

Author keywords

166Ho; Hydroxyapatite particles; Intra arterial radionuclide therapy; Liver cancer; Radiolabeled particulates

Indexed keywords

HOLMIUM; HOLMIUM 166; HYDROXYAPATITE; UNCLASSIFIED DRUG; OXIDE; RADIOISOTOPE;

ANIMAL EXPERIMENT; ARTICLE; DRUG DISTRIBUTION; DRUG PURITY; DRUG RETENTION; DRUG SYNTHESIS; DRUG TISSUE LEVEL; LIVER CANCER; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RAT; ANIMAL; CHEMISTRY; DISEASE MODEL; INTRAARTICULAR DRUG ADMINISTRATION; LIVER TUMOR; TISSUE DISTRIBUTION; WHOLE BODY IMAGING; WISTAR RAT;

ANIMALS; DISEASE MODELS, ANIMAL; DURAPATITE; HOLMIUM; INJECTIONS, INTRA-ARTICULAR; LIVER NEOPLASMS; OXIDES; RADIOISOTOPES; RATS; RATS, WISTAR; TISSUE DISTRIBUTION; WHOLE BODY IMAGING;

EID: 60849116443     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2008.0545     Document Type: Article

References (34)

1. Vente MAD, Hobbelink MGG, van het Schip AD, et al. Radionuclide liver cancer therapy: From concept to current clinical status. Anti-Cancer Agents Med Chem 2007;7:441.
2. Perkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. Ca Cancer J Clin 2005;55:74.
3. Nijsen JFW, van het Schip AD, Hennink WE, et al. Advances in nuclear oncology: Microspheres for internal radionuclide therapy of liver tumors. Curr Med Chem 2002;9:73.
4. 188Re) glass microspheres. Int J Radiat Oncl Biol Phys 1999;44:189.
5. Farmer DG, Basuttil RW. The role of multimodal therapy in the treatment of hepatocellular carcinoma. Cancer 1994;73:2669.
6. Nijsen F, Rook D, Brandt C, et al. Targeting of liver tumor in rats by selective delivery of holmium-166 loaded microspheres: A biodistribution study. Eur J Nucl Med 2001;28:743.
7. Nijsen JFW, Jonnenberg BA, Woittiez JRW, et al. Holmium-166 polylactic acid microspheres applicable for intra-arterial radionuclide therapy of hepatic malignancies: Effects of preparation and neutron activation techniques. Eur J Nucl Med 1999;26:699.
8. Meade VM, Burton MA, Gray BN, et al. Distribution of different-sized microspheres in experimental hepatic tumors. Eur J Cancer Clin Oncl 1987;23:37.
9. Anderson JH, Angerson WJ, Willmott N, et al. Regional delivery of microspheres to liver metastases: The effect of particle size and concentration on intrahepatic distribution. Br J Cancer 1991;64:1031.
10. Lambert B, Bacher K, Defreyne L, et al. 188Re-HDD/lipiodol therapy for hepatocellular carcinoma: An activity escalation study. Eur J Nucl Med Mol Imaging 2006;33:344.
11. Wang SJ, Lin WY, Chen MN, et al. Preparation and biodistribution of yttrium-90 lipiodol in rats following hepatic arterial injection. Eur J Nucl Med 1995;22:233.
12. Ackerman NB, Lien WM, Kondi ES, et al. The blood supply of experimental liver metastases. I. The distribution of hepatic artery and portal vein blood to "small" and "large" tumors. Surgery 1969;66:1067.
13. Leung WT, Lau WY, Ho S, et al. Selective internal radiation therapy with intra-arterial iodine-131-lipiodol in inoperable hepatocellular carcinoma. J Nucl Med 1994;35:1313.
14. Ehrhardt GJ, Day DE. Therapeutic use of Y-90 microsphere. Int J Radiat Appl Instrum Part B Nucl Med Biol 1987;14:233.
15. 90Y SIR-spheres: An evaluation with PET. Hepato-Gastroenterol 2007;54:910.
16. Mumper RJ, Ryo UY, Jay M. Neutron activated holmium-166-poly (L-lactic acid) microspheres: A potential agent for the internal radiation therapy of hepatic tumors. J Nucl Med 1991;32:2139.
17. Chinol M, Vallabhajosula S, Goldsmith SJ, et al. Chemistry and biological behavior of samarium-153 and rhenium-186-labeled hydroxyapatite particles: Potential radiopharmaceuticals for radiation synovectomy. J Nucl Med 1993;34:1536.
18. 166Ho labeled hydroxyapatite (HA) particles for radiosynovectomy. Nucl Med Biol 2002;29:199.
19. 175Yb-labelled hydroxyapatite: A potential agent for use in radiation synovectomy of small joints. Nucl Med Biol 2006;33:585.
20. Clunie G, Lui D, Cullum I, et al. Samarium-153-particulate hydroxyapatite for radiation synovectomy: Biodistribution data for chronic knee synovitis. J Nucl Med 1995;36:51.
21. 166Ho-HA particles for radiation synovectomy [abstract]. Ind J Nucl Med 2000;15:132.
22. 166Ho-labeled DOTA for possible use in intravascular radiation therapy. J Label Compd Radiopharm 2003;46:197.
23. Panagi Z, Beletsi A, Evangelatos G, et al. Effect of dose on the biodistribution and pharmacokinetics of PLGA and PLGA-mPEG nanoparticles. Int J Pharm 2001;221:143.
24. 177Lu-DOTMP: A viable agent for palliative radiotherapy of painful bone metastasis. Radiochim Acta 2008;96:55.
25. 166Ho-labeled polyazamacrocycle for possible use as an intravascular brachytherapy (IVBT) agent. Appl Radiat Isot 2006;64:462.
26. Lambert B, van de Wiele C. Treatment of hepatocellular carcinoma by means of radiopharmaceuticals. Eur J Nucl Med Mol Imaging 2005;32:980.
27. Raoul JL, Bourguet P, Bretangne JF, et al. Hepatic artery injection of I-131-labeled lipiodol. Part I. biodistribution study results in patients with hepatocellular carcinoma and liver metastases. Radiology 1988;168:541.
28. 188Re-HDD as a new therapeutic agent for transhepatic arterial embolization in liver cancer: Preclinical study in a rabbit liver cancer model. J Nucl Med 2003;44:2033.
29. 188Re-labelled long-chain alkyl diaminedithiol for therapy of liver cancer. Nucl Med Commun 2002;23:237.
30. 188W for fabrication of clinical scale alumina-based 188W/188W generators. Appl Radiat Isot 1994;45:1123.
31. 177Lu for radionuclide therapy. Appl Radiat Isot 2003;59:109.
32. 90Y suitable for targeted therapy. Nucl Med Biol 2008;35:245.
33. 166Ho] holmium-labeled ethylene dicysteine. Nucl Med Biol 2001;28:309.
34. Andrews JC, Walker SC, Ackermann RJ, et al. Hepatic radioembolization with yttrium-90 containing glass microspheres: Preliminary results and clinical follow up. J Nucl Med 1994;35:1637.